The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- Korosho Asks Makers to Report Errors in Standard Product Code
March 5, 2001
- Roche CEO Expects Leadership from Mr Ogawa
March 5, 2001
- Nippon Shinyaku to Terminate Development of NS-49
March 5, 2001
- JPMA Compiles Report on Globalization
March 5, 2001
- Nippon Shinyaku, SSP to Codevelop Synthetic Steroid
March 5, 2001
- Drug Wholesaler Tie-ups, M&As in 2000
March 5, 2001
- Only 70% of Hospitals Hire No. of Drs Required by Law
March 5, 2001
- SAS Institute to Start New Portal Service for R&D
March 5, 2001
- COX2 Inhibitor Expected to Prevent NSAID-induced Ulcers: Pharmacia Forum
March 5, 2001
- AstraZeneca to Launch 3 New Drugs per Year in All Major Markets
March 5, 2001
- Large Intervention Study on Hypertension Targets 9,000 Patients in Japan
March 5, 2001
- DIAGNOSTIC NEWS IN BRIEF
March 5, 2001
- Korosho to Deal with Biologics in Earnest
March 5, 2001
- Korosho to Issue GL Regarding NAT for HBV, HCV, HIV
March 5, 2001
- JPMA Invites Participation in Protein Structure Analysis Consortium
March 5, 2001
- 39 New Drugs Approved in 2000: PMSB
March 5, 2001
- Individual Health Insurance Cards to Be Introduced in April
March 5, 2001
- JPMA Calls For Maintenance of NHI Price Listing by Brand Name
March 5, 2001
- GL for Investigational Use of ES Cells Proposed
March 5, 2001
- Kemporen Proposes Series of Measures to Contain Medical Spending
March 5, 2001
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…